Pluristem Brings ARDS Associated by with COVID-19 Phase II Studies to Clinical Readout
false
פלוריסטם תרפיוטיקס אינק
2
380
PLURISTEM THERAPEUTICS INC
Corporation no:
C12337-2001
8543
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
08/07/2021
www.isa.gov.il
www.tase.co.il
Reference:
2021-02-114597
Time of broadcast:
14:41
14:39:12
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
Pluristem Brings ARDS Associated by with COVID-19 Phase II Studies to Clinical Readout
ea1439268k_pluristemEDGAR1_bannerless_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
15/06/2021
Address:
Matam Park
5
,
Haifa
31905
ISRAEL
,
Tel:
074-7107171
,
Fax:
074-7107172
E-mail address:
Info@Pluristem.Com
Company site:
www.pluristem.com
Previous names of reporting entity:
Name of the Signatory:
Yanay Yaacov
Position of Signatory in the reporting corporation:
Chief Executive Officer, Director
Name of Employer Company:
Address:
Matam Park
5
,
Haifa
31905
Telephone:
074-7107171
Facsimile:
074-7108673
E-mail:
yaky@pluristem.com
1